BR9816049A - ésteres de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-pi peridinometanol e seu uso como pró-drogas do antagonista de receptor 5ht2a mdl 110.907 - Google Patents
ésteres de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-pi peridinometanol e seu uso como pró-drogas do antagonista de receptor 5ht2a mdl 110.907Info
- Publication number
- BR9816049A BR9816049A BR9816049-4A BR9816049A BR9816049A BR 9816049 A BR9816049 A BR 9816049A BR 9816049 A BR9816049 A BR 9816049A BR 9816049 A BR9816049 A BR 9816049A
- Authority
- BR
- Brazil
- Prior art keywords
- esters
- alpha
- peridinomethanol
- 5ht2a
- dimethoxyphenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1998/021608 WO2000021930A1 (en) | 1998-10-14 | 1998-10-14 | Esters of (+)-alpha-( 2,3- dimethoxyphenyl) -1-[2-(4- fluorophenyl) ethyl]-4- piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9816049A true BR9816049A (pt) | 2001-07-03 |
Family
ID=22268079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9816049-4A BR9816049A (pt) | 1998-10-14 | 1998-10-14 | ésteres de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-pi peridinometanol e seu uso como pró-drogas do antagonista de receptor 5ht2a mdl 110.907 |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1121345A1 (pt) |
JP (1) | JP2002527422A (pt) |
KR (1) | KR100515429B1 (pt) |
CN (1) | CN1160333C (pt) |
AU (1) | AU1083099A (pt) |
BR (1) | BR9816049A (pt) |
CA (1) | CA2347469C (pt) |
CZ (1) | CZ20011331A3 (pt) |
EA (1) | EA003667B1 (pt) |
EE (1) | EE200100219A (pt) |
HK (1) | HK1039332A1 (pt) |
HR (1) | HRP20010278A2 (pt) |
HU (1) | HUP0200517A3 (pt) |
IL (2) | IL142479A0 (pt) |
NO (1) | NO320417B1 (pt) |
NZ (1) | NZ510631A (pt) |
PL (1) | PL193306B1 (pt) |
SK (1) | SK5082001A3 (pt) |
TR (1) | TR200101047T2 (pt) |
UA (1) | UA57859C2 (pt) |
WO (1) | WO2000021930A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020099076A1 (en) * | 2000-05-25 | 2002-07-25 | Richard Scheyer D. | Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis |
CN102241667B (zh) * | 2010-05-14 | 2013-10-23 | 中国人民解放军军事医学科学院毒物药物研究所 | 1-[(4-羟基哌啶-4基)甲基]吡啶-2(1h)-酮衍生物及其制备方法和用途 |
CN106892897A (zh) * | 2015-12-21 | 2017-06-27 | 上海科胜药物研发有限公司 | 一种羟哌吡酮游离碱新晶型及其制备方法 |
CN106928187A (zh) * | 2015-12-31 | 2017-07-07 | 上海奥博生物医药技术有限公司 | 一种盐酸羟哌吡酮新晶型及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0531410T3 (da) * | 1990-06-01 | 1995-01-30 | Merrell Dow Pharma | (+)-alfa-(2,3-Demethoxyphenyl)-1-(2-(4-fluorphenyl)ethyl)-4-piperidinmethanol |
-
1998
- 1998-10-14 AU AU10830/99A patent/AU1083099A/en not_active Abandoned
- 1998-10-14 CA CA002347469A patent/CA2347469C/en not_active Expired - Fee Related
- 1998-10-14 SK SK508-2001A patent/SK5082001A3/sk not_active Application Discontinuation
- 1998-10-14 CZ CZ20011331A patent/CZ20011331A3/cs unknown
- 1998-10-14 NZ NZ510631A patent/NZ510631A/en active IP Right Revival
- 1998-10-14 EA EA200100361A patent/EA003667B1/ru not_active IP Right Cessation
- 1998-10-14 HU HU0200517A patent/HUP0200517A3/hu unknown
- 1998-10-14 PL PL347318A patent/PL193306B1/pl not_active IP Right Cessation
- 1998-10-14 EE EEP200100219A patent/EE200100219A/xx unknown
- 1998-10-14 EP EP98953458A patent/EP1121345A1/en not_active Withdrawn
- 1998-10-14 WO PCT/US1998/021608 patent/WO2000021930A1/en active IP Right Grant
- 1998-10-14 JP JP2000575839A patent/JP2002527422A/ja active Pending
- 1998-10-14 TR TR2001/01047T patent/TR200101047T2/xx unknown
- 1998-10-14 KR KR10-2001-7004703A patent/KR100515429B1/ko not_active IP Right Cessation
- 1998-10-14 BR BR9816049-4A patent/BR9816049A/pt not_active Application Discontinuation
- 1998-10-14 IL IL14247998A patent/IL142479A0/xx active IP Right Grant
- 1998-10-14 CN CNB988142740A patent/CN1160333C/zh not_active Expired - Fee Related
- 1998-10-14 UA UA2001042522A patent/UA57859C2/uk unknown
-
2001
- 2001-04-05 IL IL142479A patent/IL142479A/en not_active IP Right Cessation
- 2001-04-09 NO NO20011805A patent/NO320417B1/no not_active IP Right Cessation
- 2001-04-12 HR HR20010278A patent/HRP20010278A2/hr not_active Application Discontinuation
-
2002
- 2002-02-05 HK HK02100869A patent/HK1039332A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HK1039332A1 (en) | 2002-04-19 |
EA200100361A1 (ru) | 2001-10-22 |
CZ20011331A3 (cs) | 2001-08-15 |
SK5082001A3 (en) | 2001-11-06 |
HUP0200517A2 (en) | 2002-06-29 |
CN1314887A (zh) | 2001-09-26 |
KR100515429B1 (ko) | 2005-09-20 |
PL347318A1 (en) | 2002-03-25 |
KR20010106517A (ko) | 2001-11-29 |
CA2347469C (en) | 2006-02-28 |
NO20011805L (no) | 2001-06-08 |
EE200100219A (et) | 2002-08-15 |
CN1160333C (zh) | 2004-08-04 |
TR200101047T2 (tr) | 2001-08-21 |
WO2000021930A1 (en) | 2000-04-20 |
HRP20010278A2 (en) | 2002-06-30 |
NO320417B1 (no) | 2005-12-05 |
IL142479A0 (en) | 2002-03-10 |
JP2002527422A (ja) | 2002-08-27 |
NO20011805D0 (no) | 2001-04-09 |
PL193306B1 (pl) | 2007-01-31 |
CA2347469A1 (en) | 2000-04-20 |
UA57859C2 (uk) | 2003-07-15 |
NZ510631A (en) | 2003-07-25 |
HUP0200517A3 (en) | 2002-12-28 |
EA003667B1 (ru) | 2003-08-28 |
AU1083099A (en) | 2000-05-01 |
IL142479A (en) | 2006-06-11 |
EP1121345A1 (en) | 2001-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009006018A (es) | Derivados de quinuclidinol como antagonistas de receptores muscarinicos. | |
MY124390A (en) | Substituted bicyclic derivatives useful as anticancer agents | |
CO5180642A1 (es) | Compuestos sustituidos de piperidina, procesos para su prepa racion, composiciones farmaceuticas que los contienen y su utilizacion | |
ES2160525A1 (es) | Derivados de la 4-aroilpiperidina antagonistas de los receptores ccr-3 | |
NO20000572L (no) | Indolderivater som MCP-1 reseptor antagonister | |
KR20050085991A (en) | Compounds exhibiting thrombopoietin receptor agonism | |
MY130803A (en) | New quinuclidine amide derivatives | |
ES2158813A1 (es) | Sales cuaternarias de piperidina antagonistas del receptor ccr-3 | |
UA83091C2 (en) | Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors | |
DK1159279T3 (da) | 4-Oxo-4,7-dihydro-thieno[2,3-b]pyridin-5-carboxamider som antivirale midler | |
NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
PT1499590E (pt) | Derivados de piperdina como bloqueadores do canal de potassio | |
DE602004009200D1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
IL174678A0 (en) | Arylindenophyridines and arylindenophyrimidines and their use as adenosine a2a receptor antagonist | |
PA8495101A1 (es) | Derivados de 13-metileritromicina | |
YU53100A (sh) | Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora | |
PL361282A1 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
DE69431069D1 (de) | Cyclische amidderivate als neurokinin a antagonisten | |
TR200101711T2 (tr) | Antihistaminik spiro bileşikler. | |
MXPA04005076A (es) | Derivados de 4-piperidinil alquilamina como antagonistas del receptor muscarinico. | |
BR9816049A (pt) | ésteres de (+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-pi peridinometanol e seu uso como pró-drogas do antagonista de receptor 5ht2a mdl 110.907 | |
MXPA04005313A (es) | Derivados de aminotetralin como antagonistas del receptor muscarinico. | |
HK1053109A1 (en) | Substituted homopiperidinyl benzimidazole compounds, pharmaceutical compositions comprising the same, methods for preparing them and the use for the preparation of a medicament of them | |
MXPA05011841A (es) | Metil-indoles y metil-pirrolopiridinas como agonistas adrenergicos de alfa-1. | |
DE60209014D1 (de) | Tricylische CRF Rezeptorantagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: FOI APRESENTADA ATRAVES DA PETICAO NO 40022 DE 17/08/2001 O PEDIDO DE EXAME CONTENDO UM TOTAL DE 55 REIVINDICACOES, ENTRETANTO O REQUERENTE ANEXOU UMA NOVA FOLHA 5 AO QUADRO REIVINDICATORIO, A QUAL ADICIONA UMA REIVINDICACAO AO QUADRO, PERFAZENDO UM TOTAL DE 56 REIVINDICACOES, PELO EXPOSTO, SOLICITA-SE QUE O REQUERENTE DEFINA QUAL QUADRO REIVINDICATORIO DEVE SER AXAMINADO, E QUE CASO SEJA DEFINIDO O QUE POSSUI 56 REINVIDICACOES QUE SEJA EFETUADO O PAGAMENTO DA 56O. O DEPOSITANTE DEVE TOMAR CONHECIMENTO DESTE PARECER, PODENDO MANIFESTAR-SE NO PRAZO DE 60 DIAS, CONTADOS DA DATA DA PUBLICACAO DESTE RPI. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE NAO ATENDE AOS ARTIGOS 8O E 13 DA LPI. |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |